Biblio
Export 794 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is V [Clear All Filters]
“A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 223-32, 2016.
, “Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1459-1471, 2016.
, “Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.”, J Alzheimers Dis, vol. 50, no. 2, pp. 539-46, 2016.
, “Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 49, no. 4, pp. 927-43, 2016.
, “Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 49, no. 4, pp. 927-43, 2016.
, “Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”, J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
, “A Qualitative Impairment in Face Perception in Alzheimer's Disease: Evidence from a Reduced Face Inversion Effect.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1225-36, 2016.
, “Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1193-1205, 2016.
, “Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data.”, J Alzheimers Dis, vol. 54, no. 2, pp. 801-8, 2016.
, “Relative Alterations in Blood-Based Levels of Sestrin in Alzheimer's Disease and Mild Cognitive Impairment Patients.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1147-1155, 2016.
, “Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation.”, J Alzheimers Dis, vol. 51, no. 1, pp. 57-67, 2016.
, “The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.”, J Alzheimers Dis, vol. 53, no. 2, pp. 373-92, 2016.
, “The Savvy Caregiver Program: A Probe Multicenter Randomized Controlled Pilot Trial in Caregivers of Patients Affected by Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1235-1246, 2016.
, “Self-Perceived Quality of Life Among Patients with Alzheimer's Disease: Two Longitudinal Models of Analysis.”, J Alzheimers Dis, vol. 52, no. 3, pp. 999-1012, 2016.
, “Self-Reported Change in Quality of Life with Retirement and Later Cognitive Decline: Prospective Data from the Nurses' Health Study.”, J Alzheimers Dis, vol. 52, no. 3, pp. 887-98, 2016.
, “The Societal Cost of Dementia in Singapore: Results from the WiSE Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 439-49, 2016.
, “Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 69-79, 2016.
, “Specific Triazine Herbicides Induce Amyloid-β42 Production.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1593-1605, 2016.
, “Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 53, no. 1, pp. 107-16, 2016.
, “Stroke, Vascular Dementia, and Alzheimer's Disease: Molecular Links.”, J Alzheimers Dis, vol. 54, no. 2, pp. 427-43, 2016.
, “Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
, “Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
, “Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
, “Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1373-1383, 2016.
, “Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.”, J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
,